Literature DB >> 20956995

Does diabetes mellitus increase the risk of high-grade prostate cancer in patients undergoing radical prostatectomy?

F Abdollah1, A Briganti, N Suardi, A Gallina, U Capitanio, A Salonia, A Cestari, G Guazzoni, P Rigatti, F Montorsi.   

Abstract

The objective was to test the hypothesis that in patients with prostate cancer undergoing radical prostatectomy (RP), diabetic patients are at a higher risk of harboring a high-grade tumor than non-diabetic patients. We examined 2060 consecutive men who underwent RP between 2001 and 2009. Of them, 7.1% had type 2 diabetes mellitus (DM). A high-grade tumor was defined as having a Gleason score ≥ 8. Univariable and multivariable logistic regression analyses were used to test the relationship between type 2 DM and high-grade tumor. Mean patient age was 64 years (range: 45-85). Mean total PSA level was 9 ng ml(-1) (range: 1-89.5). A significantly higher percentage of diabetic patients had high-grade tumor on biopsy (16.3 vs 7.6%; P = 0.001) and on RP specimen (21.1 vs 11.7%; P = 0.001) in comparison with non-diabetic patients. In multivariable analyses, DM was an independent predictor of high-grade tumor on biopsy (odds ratio = 2.31, P = 0.001) and on final pathological specimen (odds ratio = 2.22, P = 0.002). In patients undergoing RP, those with type 2 DM had a higher risk of harboring a poorly differentiated tumor on final pathological examination.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20956995     DOI: 10.1038/pcan.2010.41

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  15 in total

1.  Statins and Finasteride Use Differentially Modify the Impact of Metformin on Prostate Cancer Incidence in Men with Type 2 Diabetes.

Authors:  Wang Chen-Pin; Hernandez Javier; Carlos Lorenzo; John R Downs; Ian M Thompson; Bradley Pollock; Donna Lehman
Journal:  Ann Transl Med Epidemiol       Date:  2014

2.  Diabetes mellitus is associated with short prostate-specific antigen doubling time after radical prostatectomy.

Authors:  Jong Jin Oh; Sung Kyu Hong; Sangchul Lee; Seung June Sohn; Sang Eun Lee
Journal:  Int Urol Nephrol       Date:  2012-09-29       Impact factor: 2.370

3.  The association between overall survival of prostate cancer patients and hypertension, hyperglycemia, and overweight in Southern China: a prospective cohort study.

Authors:  Hua Xu; Li-min Zhang; Jun Liu; Guan-xiong Ding; Qiang Ding; Hao-wen Jiang
Journal:  J Cancer Res Clin Oncol       Date:  2013-02-27       Impact factor: 4.553

4.  Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality.

Authors:  Daniel E Spratt; Chi Zhang; Zachary S Zumsteg; Xin Pei; Zhigang Zhang; Michael J Zelefsky
Journal:  Eur Urol       Date:  2012-12-14       Impact factor: 20.096

5.  Tumor features and survival after radical prostatectomy among antidiabetic drug users.

Authors:  R M Joentausta; P M Kujala; T Visakorpi; T L J Tammela; T J Murtola
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-08-09       Impact factor: 5.554

6.  Metformin for Reducing Racial/Ethnic Difference in Prostate Cancer Incidence for Men with Type II Diabetes.

Authors:  Chen-Pin Wang; Donna M Lehman; Yui-Wing F Lam; John G Kuhn; Devalingam Mahalingam; Steven Weitman; Carlos Lorenzo; John R Downs; Elizabeth A Stuart; Javier Hernandez; Ian M Thompson; Amelie G Ramirez
Journal:  Cancer Prev Res (Phila)       Date:  2016-03-29

7.  Association between Types of Chronic Conditions and Cancer Stage at Diagnosis among Elderly Medicare Beneficiaries with Prostate Cancer.

Authors:  Amit D Raval; Suresh Madhavan; Malcolm D Mattes; Usha Sambamoorthi
Journal:  Popul Health Manag       Date:  2016-03-31       Impact factor: 2.459

8.  The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer.

Authors:  Jennifer H Gunter; Amy A Lubik; Ian McKenzie; Michael Pollak; Colleen C Nelson
Journal:  Adv Urol       Date:  2012-04-03

9.  Statin use as a moderator of metformin effect on risk for prostate cancer among type 2 diabetic patients.

Authors:  Donna M Lehman; Carlos Lorenzo; Javier Hernandez; Chen-Pin Wang
Journal:  Diabetes Care       Date:  2012-03-28       Impact factor: 19.112

10.  New players for advanced prostate cancer and the rationalisation of insulin-sensitising medication.

Authors:  Jennifer H Gunter; Phoebe L Sarkar; Amy A Lubik; Colleen C Nelson
Journal:  Int J Cell Biol       Date:  2013-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.